Multiple Manufacturers

UPLIZNA

Manufacturer:

Multiple Manufacturers

Uplizna HCPCS:

J1823

HCPCS Code Descriptor:

Injection, inebilizumab-cdon, 1 mg

Category:

J Code

Uplizna NDCs:

72677-0551-01, 75987-0150-03

Primary Type:

Neurology

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

72677-0551-01

About Uplizna:

UPLIZNA is a Neurology drug manufactured by Horizon Therapeutics and administered via the Intravenous route of administration. The J Code: J1823 is aligned to the drug UPLIZNA.

UPLIZNA is a cytolytic antibody commonly used to treat neuromyelitis optica spectrum disorder. It works by binding CD19, an antigen present on the surface of mature B cells and pre-B cells. Once UPLIZNA (J1823) binds CD19, the cell lyses UPLIZNA is used in adult patients who are anti-aquaporin-4 antibody positive. Patient assistance for this medication can be found through Horizon Therapeutics.

ACCESS PRICING AND MORE BY REGISTERING

J1823 Added Date:

January 1, 2021

J1823 Effective Date:

January 1, 2021

J1823 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Uplizna billing and coding information.
Uplizna patient assistance information can be found through Horizon By Your Side at the URL: https://www.horizontherapeutics.com/patients/patient-support
UPLIZNA prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for UPLIZNA. Please check back in a few weeks.